Validation of the inflammatory bowel disease disability index for self-report and development of an item-reduced version.


Journal

Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 25 03 2018
revised: 28 08 2018
accepted: 16 09 2018
pubmed: 3 10 2018
medline: 6 5 2019
entrez: 3 10 2018
Statut: ppublish

Résumé

The Inflammatory Bowel Disease Disability Index (IBD-DI) is a measure of disability in inflammatory bowel disease (IBD). The IBD-DI is validated for use as a clinical interview but not for use as a self-report questionnaire. We aimed to validate the IBD-DI for self-report (IBD-DI-SR) and to reduce the number of items, using IBD patients from two centers. Between April and August 2017, ambulatory IBD patients were recruited from Christchurch Hospital, New Zealand and Concord Hospital, Australia. The IBD-DI clinical interview version was compared with a self-report version. Participants were randomized to do the clinical interview or self-report first. Validation of the IBD-DI-SR involved calculating the correlation coefficient between the clinician completed and self-reported version of the IBD-DI and Cronbach's α of internal consistency of the IBD-DI-SR. To create an item-reduced version, multiple linear regression was used. The R One hundred fourteen patients (57 from Christchurch and 57 from Sydney) completed the IBD-DI-SR validation phase, of whom 63 had Crohn's disease and 51 had ulcerative colitis. The Pearson correlation coefficient between the IBD-DI-SR and IBD-DI is 0.90 (P < 0.001), and Cronbach's α of the IBD-DI-SR was 0.86. The item-reduced version of the IBD-DI-SR consisted of eight questions instead of 28, explaining 77% of the variance. The IBD-DI-SR has demonstrated reliability and validity. The item-reduced IBD-DI-SR is a concise self-report instrument for measuring IBD disability, which makes the IBD-DI more widely usable.

Sections du résumé

BACKGROUND AND AIM OBJECTIVE
The Inflammatory Bowel Disease Disability Index (IBD-DI) is a measure of disability in inflammatory bowel disease (IBD). The IBD-DI is validated for use as a clinical interview but not for use as a self-report questionnaire. We aimed to validate the IBD-DI for self-report (IBD-DI-SR) and to reduce the number of items, using IBD patients from two centers.
METHODS METHODS
Between April and August 2017, ambulatory IBD patients were recruited from Christchurch Hospital, New Zealand and Concord Hospital, Australia. The IBD-DI clinical interview version was compared with a self-report version. Participants were randomized to do the clinical interview or self-report first. Validation of the IBD-DI-SR involved calculating the correlation coefficient between the clinician completed and self-reported version of the IBD-DI and Cronbach's α of internal consistency of the IBD-DI-SR. To create an item-reduced version, multiple linear regression was used. The R
RESULTS RESULTS
One hundred fourteen patients (57 from Christchurch and 57 from Sydney) completed the IBD-DI-SR validation phase, of whom 63 had Crohn's disease and 51 had ulcerative colitis. The Pearson correlation coefficient between the IBD-DI-SR and IBD-DI is 0.90 (P < 0.001), and Cronbach's α of the IBD-DI-SR was 0.86. The item-reduced version of the IBD-DI-SR consisted of eight questions instead of 28, explaining 77% of the variance.
CONCLUSIONS CONCLUSIONS
The IBD-DI-SR has demonstrated reliability and validity. The item-reduced IBD-DI-SR is a concise self-report instrument for measuring IBD disability, which makes the IBD-DI more widely usable.

Identifiants

pubmed: 30276858
doi: 10.1111/jgh.14496
doi:

Types de publication

Journal Article Multicenter Study Observational Study Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

92-102

Informations de copyright

© 2018 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Auteurs

Emma Paulides (E)

Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand.
Department of Gastroenterology and Hepatology, VU University Medical Centre, Amsterdam, The Netherlands.

Catherine Kim (C)

University of New South Wales, Sydney, New South Wales, Australia.

Chris Frampton (C)

Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand.

Richard B Gearry (RB)

Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand.
Canterbury District Health Board, Christchurch, New Zealand.

Tim Eglinton (T)

Canterbury District Health Board, Christchurch, New Zealand.
Department of Surgery, Christchurch Hospital, Christchurch, New Zealand.

Rupert W Leong (RW)

University of New South Wales, Sydney, New South Wales, Australia.
Department of Gastroenterology and Hepatology, Concord Hospital, Sydney, New South Wales, Australia.

Nanne K H de Boer (NKH)

Department of Gastroenterology and Hepatology, VU University Medical Centre, Amsterdam, The Netherlands.

Chris J J Mulder (CJJ)

Department of Gastroenterology and Hepatology, VU University Medical Centre, Amsterdam, The Netherlands.

Andrew M McCombie (AM)

Department of Surgery, Christchurch Hospital, Christchurch, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH